Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13430554 | 0.87 | ESR1 (0.34) | — | |
| SCHEMBL1903629 | 0.86 | CYP2C9 (0.35) | LMNACYP1A2CYP3A4CYP2D6MAPT | |
| SCHEMBL29351133 | 0.86 | CYP2C9 (0.35) | LMNACYP1A2CYP3A4CYP2D6MAPT | |
| SCHEMBL13916008 | 0.86 | CYP2C9 (0.35) | LMNACYP1A2CYP3A4CYP2D6MAPT | |
| SCHEMBL4712395 | 0.82 | ALDH1A1 (0.36) | LMNACYP1A2CYP3A4CYP2D6MAPT | |
| SCHEMBL4406652 | 0.81 | ESR1 (0.34) | LMNAMAPTCYP2C9CYP2C19PIK3CD | |
| SCHEMBL5768823 | 0.81 | CYP2C9 (0.38) | LMNACYP1A2CYP3A4CYP2D6MAPT | |
| SCHEMBL14567601 | 0.80 | ALDH1A1 (0.37) | CYP1A2CYP3A4MAPTCYP2C9HPGD | |
| SCHEMBL6392586 | 0.76 | CYP2C9 (0.35) | LMNACYP1A2CYP3A4CYP2D6MAPT | |
| SCHEMBL4409924 | 0.74 | CHRNB4 (0.53) | LMNAMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100062046-A1 | POLYMORPHS OF NICOTINIC INTERMEDIATES | ALLEN DOUGLAS J M | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100062046-A1 | POLYMORPHS OF NICOTINIC INTERMEDIATES | NAPRT, NAMPT, NNMT | LMNA 743/4885CYP1A2 180/4885CYP3A4 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.